Verona Pharma (VRNA)
| Bid | 71.64 |
| Market Cap | 6.1B |
| Revenue (ttm) | 118.53M |
| Net Income (ttm) | -164.02M |
| EPS (ttm) | -2.16 |
| PE Ratio (ttm) | -33.23 |
| Forward PE | 176.12 |
| Analyst | Strong Buy |
| Ask | 71.88 |
| Volume | 634,386 |
| Avg. Volume (20D) | 1,623,626.1 |
| Open | 72.80 |
| Previous Close | 72.07 |
| Day's Range | 69.33 - 72.97 |
| 52-Week Range | 11.39 - 74.18 |
| Beta | 0.16 |
About VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the ...
Analyst Forecast
According to 5 analyst ratings, the average rating for VRNA stock is "Strong Buy." The 12-month stock price forecast is $72, which is an increase of 0.31% from the latest price.
Stock ForecastsEarnings Surprise
3 weeks ago · seekingalpha.com
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is CriticalOhtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is so...
